Goyal Aman, Tariq Muhammad Daoud, Khan Abdul Moiz, Hurjkaliani Sonia, Ahsan Areeba, Saeed Humza, Trivedi Rhea, Mahalwar Gauranga, Daoud Mohamed, Belur Agastya D
Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
Department of Critical Care Medicine, Alchemist Hospitals, Panckula, India.
Heart Rhythm O2. 2025 Mar 5;6(6):753-765. doi: 10.1016/j.hroo.2025.02.020. eCollection 2025 Jun.
Heart failure (HF) affects millions globally, causing severe symptoms and poor prognosis. Cardiac resynchronization therapy (CRT) has been shown to improve heart function and quality of life in HF patients with electrical dyssynchrony, but its effectiveness in diabetic patients remains unclear due to the complexities associated with diabetes.
This study evaluates the impact of diabetes mellitus on CRT by comparing outcomes between diabetic and nondiabetic patients through a meta-analysis.
A comprehensive literature search identified studies on CRT in HF patients both with and without diabetes mellitus. Pooled risk ratios (RRs) and mean differences were calculated using a random-effects model with 95% confidence intervals and statistical significance set at .05.
Analysis of 13 observational studies involving 20,073 participants revealed that diabetic patients had a significantly increased risk of all-cause mortality (RR 1.34, .00001) and cardiovascular death (RR 1.49, .002) compared with nondiabetic patients. However, no statistically significant differences were observed between groups in the risk of stroke (RR 3.99, .05), myocardial infarction (RR 1.16, .30), changes in left ventricular (LV) ejection fraction ( = .22), LV end-systolic volume ( = .10), and LV end-diastolic volume ( = .63).
These findings suggest that diabetic patients undergoing CRT face a higher risk of all-cause and cardiovascular mortality compared with nondiabetic patients. The increased mortality risk highlights the need for tailored treatment strategies, emphasizing the judicious use of CRT in diabetic patients.
心力衰竭(HF)在全球影响着数百万人,会导致严重症状和不良预后。心脏再同步治疗(CRT)已被证明可改善存在电不同步的HF患者的心脏功能和生活质量,但由于糖尿病相关的复杂性,其在糖尿病患者中的有效性仍不明确。
本研究通过荟萃分析比较糖尿病患者和非糖尿病患者的结局,以评估糖尿病对CRT的影响。
全面的文献检索确定了有关有或无糖尿病的HF患者接受CRT的研究。使用随机效应模型计算合并风险比(RRs)和平均差,并设定95%置信区间,统计学显著性设定为.05。
对涉及20,073名参与者的13项观察性研究的分析显示,与非糖尿病患者相比,糖尿病患者全因死亡率(RR 1.34,.00001)和心血管死亡风险(RR 1.49,.002)显著增加。然而,两组在中风风险(RR 3.99,.05)、心肌梗死(RR 1.16,.30)、左心室(LV)射血分数变化( =.22)、LV收缩末期容积( =.10)和LV舒张末期容积( =.63)方面未观察到统计学显著差异。
这些发现表明,与非糖尿病患者相比,接受CRT的糖尿病患者面临更高的全因和心血管死亡风险。死亡率增加凸显了制定个性化治疗策略的必要性,强调在糖尿病患者中明智地使用CRT。